Announcements Trials
Browse Landscape

Phase

Phase 2 4Phase 1 3Phase 1/2 1

Status

Recruiting 22Unknown 19Completed 9Not yet recruiting 8Terminated 3Active not recruiting 3Withdrawn 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other solid neoplasm 1

Conditions

Solid Tumor 1

Interventions

Cyclophosphamide 28pembrolizumab 22Bevacizumab 18Fluorouracil 17Cisplatin 17Nivolumab 16Capecitabine 16Leucovorin 15Dexamethasone 14Carboplatin 13avelumab 12Oxaliplatin 12Radiosurgery 11Gemcitabine 11Rituximab 10Radiotherapy 10Lenalidomide 10ALT-803 10venetoclax 9fludarabine 9Taxes 9Omacor 9Azacitidine 9130-nm albumin-bound paclitaxel 9Paclitaxel 8Docetaxel 8Bortezomib 8fludarabine phosphate 7Melphalan 7Irinotecan 7

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 1/2 × Withdrawn × toripalimab × Clear all
NCT05165849 2022-05-20

A Study of GFS101A in Combination With Toripalimab in Patients With Advanced Solid Tumors

Genfleet Therapeutics (Shanghai) Inc.

Phase 1/2 Withdrawn
Other solid neoplasm

Solid Tumor

Data powered by HemOnc (CC BY 4.0) Colophon âš¡